Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

Introduction: The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment. However, ultimately many patients still relapse,...

Full description

Bibliographic Details
Main Authors: Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N. Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J. Cheadle, Timothy M. Illidge
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
CD20
antibody
lymphoma
tumor microenvironment
stroma
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2023.1270398/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2023.1270398/full

Similar Items